Abstract
The focal distribution of the dopamine (DA) D3 receptor in brain regions implicated in emotional and cognitive functions has made this target a main focus of drug discovery efforts. This paper will review the most recent lines of research in support of the use of selective DA D3 receptor antagonists for the pharmacotherapeutic management of drug addiction: (1) expression of the DA D3 receptor in the rodent and human brain; (2) changes in expression of the DA D3 receptor following exposure to drugs of abuse, and (3) efficacy of selective DA D3 receptor antagonists in preclinical paradigms assessing the behavioral effects of drugs such as cocaine, nicotine, alcohol, methamphetamine, and heroin. This manuscript, however, will not review the effects of nonselective DA D2/D3 receptor antagonists or partial D3 receptor agonists. Growing evidence suggests that selective DA D3 receptor antagonists do not affect the primary reinforcing effects of drugs of abuse, but rather seem to regulate the motivation to self-administer drugs under schedules of reinforcement that require an increase in work demand. In addition, selective antagonism at DA D3 receptors appears to disrupt significantly the responsiveness to drug-associated stimuli that play a key role in reinstatement of drug-seeking behavior. These preclinical findings will be discussed in the context of translational research relevant to the design of early clinical trials and hypothesis testing in humans.
Keywords: Addiction, dopamine, D3 receptor, impulse control disorder, selective antagonists
CNS & Neurological Disorders - Drug Targets
Title: Selective Antagonism at Dopamine D3 Receptors as a Target for Drug Addiction Pharmacotherapy: A Review of Preclinical Evidence
Volume: 7 Issue: 5
Author(s): Christian Heidbreder
Affiliation:
Keywords: Addiction, dopamine, D3 receptor, impulse control disorder, selective antagonists
Abstract: The focal distribution of the dopamine (DA) D3 receptor in brain regions implicated in emotional and cognitive functions has made this target a main focus of drug discovery efforts. This paper will review the most recent lines of research in support of the use of selective DA D3 receptor antagonists for the pharmacotherapeutic management of drug addiction: (1) expression of the DA D3 receptor in the rodent and human brain; (2) changes in expression of the DA D3 receptor following exposure to drugs of abuse, and (3) efficacy of selective DA D3 receptor antagonists in preclinical paradigms assessing the behavioral effects of drugs such as cocaine, nicotine, alcohol, methamphetamine, and heroin. This manuscript, however, will not review the effects of nonselective DA D2/D3 receptor antagonists or partial D3 receptor agonists. Growing evidence suggests that selective DA D3 receptor antagonists do not affect the primary reinforcing effects of drugs of abuse, but rather seem to regulate the motivation to self-administer drugs under schedules of reinforcement that require an increase in work demand. In addition, selective antagonism at DA D3 receptors appears to disrupt significantly the responsiveness to drug-associated stimuli that play a key role in reinstatement of drug-seeking behavior. These preclinical findings will be discussed in the context of translational research relevant to the design of early clinical trials and hypothesis testing in humans.
Export Options
About this article
Cite this article as:
Heidbreder Christian, Selective Antagonism at Dopamine D3 Receptors as a Target for Drug Addiction Pharmacotherapy: A Review of Preclinical Evidence, CNS & Neurological Disorders - Drug Targets 2008; 7 (5) . https://dx.doi.org/10.2174/187152708786927822
DOI https://dx.doi.org/10.2174/187152708786927822 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Quorum-Sensing Inhibitors and Biofilms
Anti-Infective Agents in Medicinal Chemistry Outer Surface Proteins of Borrelia: Peerless Immune Evasion Tools
Current Protein & Peptide Science Identification of Attention Deficit/Hyperactivity Disorder in Children Using Multiple ERP Features
Current Bioinformatics Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Osteogenic Differentiation Factors of Multipotent Mesenchymal Stromal Cells in the Current Understanding
Current Pharmaceutical Design Depression in Older Persons with Mobility Limitations
Current Pharmaceutical Design Stretch, Shrink, and Shatter the Rhythms: The Intrinsic Circadian Period in Mania and Depression
CNS & Neurological Disorders - Drug Targets Implication of Complement System and its Regulators in Alzheimers Disease
Current Neuropharmacology Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry The Scalability of Wet Ball Milling for The Production of Nanosuspensions
Pharmaceutical Nanotechnology In memory of Prof. Stephen Drake Skaper
CNS & Neurological Disorders - Drug Targets Epidemiology and Clinical Presentation of Stress-Related Peptic Damage and Chronic Peptic Ulcer
Current Molecular Medicine α7 Nicotinic Acetylcholine Receptors: A Therapeutic Target in the Structure Era
Current Drug Targets Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of Glycolytic and Mitochondrial Metabolism by Ras
Current Pharmaceutical Biotechnology Transcranial Magnetic Stimulation in Schizophrenia: The Contribution of Neuroimaging
Current Topics in Medicinal Chemistry Endocannabinoid System: A Promising Therapeutic Target for the Treatment of Haematological Malignancies?
Current Medicinal Chemistry Amyloid Precursor Protein Processing in Vivo - Insights from a Chemically- Induced Constitutive Overactivation of Protein Kinase C in Guinea Pig Brain
Current Medicinal Chemistry Challenges in Vascular Repair by Endothelial Progenitor Cells in Diabetic Patients
Cardiovascular & Hematological Disorders-Drug Targets